CALYPSO BIOTECH
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
CALYPSO BIOTECH
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2013-01-01
Address:
Plan-les-ouates, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.calypsobiotech.com
Total Employee:
11+
Status:
Active
Contact:
+41225523307
Email Addresses:
[email protected]
Total Funding:
30.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series A - Calypso Biotech
M Ventures
M Ventures investment in Series A - Calypso Biotech
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series A - Calypso Biotech
Gilde Healthcare
Gilde Healthcare investment in Series A - Calypso Biotech
Inkef
Inkef investment in Series A - Calypso Biotech
Eclosion SA
Eclosion SA investment in Seed Round - Calypso Biotech
M Ventures
M Ventures investment in Seed Round - Calypso Biotech
Official Site Inspections
http://www.calypsobiotech.com
- Host name: ns8.medialook.net
- IP address: 51.255.79.159
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Calypso Biotech"
Calypso Biotech - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +41225523307 Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as …See details»
Calypso Biotech Company Overview, Contact Details
[email protected]: 50%. See more formats. Frequently Asked Questions Where is Calypso Biotech 's headquarters located? Calypso Biotech 's main headquarters is located at …See details»
Calypso Biotech - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for Calypso Biotech. Use the PitchBook Platform to explore the full profile.See details»
Calypso Biotech - Overview, News & Similar companies - ZoomInfo
Sep 9, 2021 View Calypso Biotech (www.calypsobiotech.com) location in Geneva, Switzerland , revenue, industry and description. Find related and similar companies as well as employees …See details»
Novartis’ Strategic Acquisition of Calypso: A Game-Changer in ...
Jan 10, 2024 Learn more about the company via its website www.calypsobiotech.com. About Novartis AG. Novartis AG, headquartered in Basel, Switzerland, stands as a formidable Swiss …See details»
Novartis acquires Calypso Biotech - 2024-01-08 - Crunchbase
Jan 8, 2024 Acquiring Organization: Novartis Novartis is a healthcare company that provides solutions to address the evolving needs of patients worldwide. Announced Date Jan 8, 2024; …See details»
Calypso Biotech SA – Swiss Biotech
Calypso Biotech, a clinical-stage spin-off from Merck Serono, develops therapeutic biologics that targets Interleukin-15 (IL-15). Its lead product is a best-in-class anti-IL-15 antibody CALY-002 …See details»
Calypso Biotech - Company Profile - Tracxn
Dec 9, 2024 Calypso Biotech - Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases. Acquired by Novartis. Raised a total funding of $36.4M over 4 …See details»
Calypso Press release AGC Biologics - Calypso biotech
Biotech, please see https://www.calypsobiotech.com About AGC Biologics AGC Biologics is a leading global Contract Development and Manufacturing Organization, with a strong …See details»
Calypso Biotech - Products, Competitors, Financials, Employees ...
Novartis Acquires Calypso Biotech in Strategic Move for Innovative Immunotherapy. Jan 31, 2024. January 29, 2024 Recently, European immunotherapy biotech company Calypso …See details»
AGC Biologics & Calypso Biotech BV Announce Manufacturing …
Feb 19, 2019 For more information on Calypso Biotech, please see https://www.calypsobiotech.com. About AGC Biologics AGC Biologics is a leading global …See details»
Calypso enters into agreement to be acquired by Novartis
Jan 8, 2024 Contact: [email protected] . Title: Press_Release_Calypso-Novartis_2024.01.08_for_site-5.pdf Author: Obuobi, Kwame Created Date: 1/9/2024 11:46:03 …See details»
Gilde Healthcare announces Calypso to be acquired by Novartis …
Jan 8, 2024 The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications Calypso is a …See details»
Novartis Acquires Calypso Biotech for up to $425 Million
On Jan. 8, 2024, Calypso Biotech, a European immunotherapy biotech company focused on the research and development of novel biologics, announced it had agreed to be acquired by …See details»
Novartis to acquire Calypso Biotech for autoimmune treatment
Jan 8, 2024 The deal will give Novartis full rights to an antibody Calypso is working on to treat various autoimmune diseases. Calypso Biotech, a Dutch company developing treatments for …See details»
Calypso Biotech Completes CALY-002 Clinical Batch …
Jun 18, 2020 For more information on Calypso Biotech, please see www.calypsobiotech.com. About AGC Biologics: AGC Biologics is a leading global Contract Development and …See details»
08 January 2024: Calypso enters into agreement to be ... - Calypso …
08 January 2024: Calypso enters into agreement to be acquired by Novartis. Posted at h in Press release by calypsobiotech. Click to see full press releaseSee details»
Calypso biotech | calypsobiotech
Jan 8, 2024 Jos Houbiers, CMO of Calypso Biotech, gives an oral presentation entitled: “Interim resuts from a first-in-human study of the anti-IL-15 antibody CALY-002 for treating Celiac …See details»
Calypso Biotech - Gilde Healthcare
Calypso Biotech is a biopharmaceutical company specializing in the development of therapeutic antibodies against severe (auto)immune diseases. Calypso’s lead program, CALY-002, is a …See details»
2021 - Calypso biotech
09 September 2021: Calypso Biotech announces first patient with Celiac Disease dosed in anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 Phase 1b Trial, and extension of Series …See details»